| Literature DB >> 31818259 |
Kosei Takagi1,2, Piotr Domagala3,4, Wojciech G Polak3, Stefan Buettner3, Jan N M Ijzermans3.
Abstract
BACKGROUND: The clinical value of the controlling nutritional status (CONUT) score in hepatocellular carcinoma (HCC) has increased. The aim of this meta-analysis was to systematically review the association between the CONUT score and outcomes in patients undergoing hepatectomy for HCC.Entities:
Keywords: Controlling nutritional status (CONUT) score; Hepatocellular carcinoma; Meta-analysis; Outcome
Mesh:
Year: 2019 PMID: 31818259 PMCID: PMC6902571 DOI: 10.1186/s12876-019-1126-6
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1PRISMA 2009 Flow Diagram
Literatures of the effects of the CONUT score in patients undergoing hepatectomy for hepatocellular carcinoma
| Study | Year | Country | Study design | Number (Male) | Tumor stage | Cut-off for high CONUT group | Prevalence of high CONUT score | End points | Qualitya |
|---|---|---|---|---|---|---|---|---|---|
| Takagi et al. [ | 2017 | Japan | Retrospective Single center | 295 (241) | I: 36 II: 126 III: 92 IV: 41 | ≥3 | 40.0% | OS RFS | 7 |
| Harimoto et al. [ | 2017 | Japan | Retrospective Single center | 357 (270) | I: 58 II: 187 III: 93 IV: 19 | ≥4 | 19.3% | OS RFS | 6 |
| Takagi et al. [ | 2018 | Japan | Retrospective Single center | 331 (269) | I + II: 185 III + IV: 146 | ≥5 | 9.1% | Complications | 6 |
| Harimoto et al. [ | 2018 | Japan | Retrospective Multi-center | 2461 (1785) | I + II: 1437 III + IV: 1024 | ≥4 | 21.9% | OS RFS | 6 |
| Li et al. [ | 2018 | China | Retrospective Single center | 1334 (1136) | n.a. | ≥8b | 49.4% | Complications | 8 |
| Wang et al. [ | 2018 | China | Retrospective Single center | 209 (172) | BCLC stage A: 126 B: 40 C: 43 | ≥3 | 34.5% | OS RFS PHR | 6 |
| Lin et al. [ | 2019 | China | Retrospective Single center | 380 (333) | I + II: 304 III + IV: 76 | ≥2 | 49.2% | OS RFS | 8 |
aScore from a maximum of 9 evaluated by the Newcastle–Ottawa quality assessment scale for cohort studies [8].
bEvaluated by postoperative CONUT score
CONUT controlling nutritional status, OS overall survival, RFS recurrence-free survival, n.a not available, BCLC stage Barcelona clinic liver cancer stage, PHR postoperative hepatitis B virus reactivation
Literatures reporting the effects of the CONUT score on postoperative outcome in patients undergoing hepatectomy for hepatocellular carcinoma
| Study | Complications | Mortality | Recurrence-free survival | Overall survival |
|---|---|---|---|---|
| Takagi et al. [ | Major (CDc ≥ III): 15 vs 14% ( | n.a. | 5-year: 27.9 vs 41.4% ( HR 1.64 (1.15–2.30), | 5-year: 61.9 vs 74.9% ( HR 2.50 (1.47–4.23), |
| Harimoto et al. [ | Major (CDc ≥ III): 20.3 vs 14.9% ( | n.a. | 5-year: 8.8 vs 38.0% ( HR 1.51 (1.06–2.15), | 5-year: 47.6 vs 78.0% ( HR 2.16 (1.25–3.72), |
| Takagi et al. [ | Overall (CDc ≥ II): 56.7 vs 45.5% ( Major (CDc ≥ III): 23.3 vs 13.6% ( | 10.0 vs 1.3% ( OR 9.41 (1.15–77.4), | n.a. | n.a. |
| Harimoto et al. [ | Major (CDc ≥ III): 17.7 vs 11.0% ( | n.a. | HR 1.219 (1.06–1.40), | HR 1.223 (1.06–1.41), |
| Li et al. [ | Major (CDc ≥ III): 15.6 vs 6.2% ( OR 2.05 (1.37–3.01), | 2.6 vs 0.4% ( | n.a. | n.a. |
| Wang et al. [ | Overall: 74.3 vs 59.3% ( | n.a. | 5-year: 10.0 vs 9.6% ( HR 1.54 (1.10–2.16), | 5-year: 31.3 vs 44.0% ( HR 1.62 (1.05–2.51), |
| Lin et al. [ | Overall (CDc ≥ II): 29.4 vs 23.3% ( | n.a. | 5-year: 37.2 vs 47.6% ( HR 1.36 (1.00–1.85), | 5-year: 66.7 vs 82.8% ( HR 2.40 (1.74–4.25), |
Data are shown for high CONUT group versus low CONUT group. Odds ratio (OR) and Hazard ration (HR) is shown with 95% confidence interval. aMultivariable analysis. bUnivariate analysis
CONUT controlling nutritional status, CDc Clavien–Dindo classification, n.a not available
Fig. 2Forest plots demonstrating primary outcomes in terms of high CONUT group versus low CONUT group. a Overall survival; and (b) Recurrence-free survival
Fig. 3Forest plots demonstrating secondary outcomes in terms of high CONUT group versus low CONUT group. a Major complications (CDc ≥ III); (b) Child-Pugh B; (c) Liver cirrhosis; (d) ICGR15; (e) Tumor size; (f) Tumor number (multiple); (g) Poor differentiation; and (h) Microvascular invasion